After completing Kisunla treatment, patients and caregivers enter a critical monitoring phase rather than an end point. Unlike many medications that stop working when you stop taking them, Kisunla’s effects persist in the brain after infusions end, requiring ongoing imaging studies and cognitive assessments to track what happens next.
The transition from active treatment involves careful medical supervision, not a simple return to baseline care, because the drug continues to work on amyloid plaques in the brain even after the last infusion has been administered. For someone like Margaret, a 68-year-old with early Alzheimer’s who completed her Kisunla treatment cycle, “completing” didn’t mean getting better and moving on—it meant entering a new phase where her doctors needed to see whether the slowing of cognitive decline would hold, improve, or reverse course. Her neurologist scheduled regular cognitive testing, brain imaging, and blood work to document the outcomes over months and years following her final infusion.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Long Does Kisunla Continue Working After Treatment Ends?
- Monitoring Requirements After Treatment Completion
- What If Cognitive Decline Resumes After Treatment?
- Managing Amyloid-Related Imaging Abnormalities (ARIA)
- Adjusting Medications and Managing Side Effects
- Caregiving and Lifestyle Adjustments After Treatment
- Planning for Subsequent Treatments or Care Transitions
- Frequently Asked Questions
How Long Does Kisunla Continue Working After Treatment Ends?
kisunla doesn’t disappear from the brain immediately after your last infusion. The monoclonal antibody continues binding to amyloid plaques and gradually clears from the body over weeks and months, which means treatment effects extend beyond the infusion schedule. This extended activity is one reason why post-treatment monitoring is not optional—doctors need to observe whether cognitive improvements stabilize, slow further decline, or plateau at a new baseline.
The persistence of Kisunla in the brain varies between individuals based on metabolism, immune response, and other biological factors. Some people maintain benefits longer than others, and the rate at which the drug clears can influence how quickly cognitive symptoms might resume progressing. This individual variation means there’s no universal timeline for what to expect; one patient’s experience after treatment cannot predict another’s.
Monitoring Requirements After Treatment Completion
Doctors typically schedule follow-up imaging—usually MRI or PET scans—at regular intervals after Kisunla treatment ends to assess whether amyloid plaques have remained reduced or begun accumulating again. These scans aren’t routine health screenings; they’re essential data points that guide whether additional treatment, a different medication, or supportive care adjustments are needed. A significant limitation of this monitoring is that brain imaging doesn’t always correlate perfectly with how someone actually functions day-to-day, creating a gap between what the scans show and what the patient experiences.
Cognitive testing through neuropsychological assessments tracks memory, attention, language, and executive function over time. These tests are more predictive of real-world outcomes than imaging alone, but they can be lengthy, taxing on the person being tested, and sometimes difficult to interpret when small fluctuations occur naturally. Insurance coverage for ongoing monitoring varies widely, and many people find that post-treatment follow-up requires out-of-pocket expenses or advocacy to ensure tests are approved and completed on schedule.
What If Cognitive Decline Resumes After Treatment?
Some patients experience a return to progressive cognitive decline after Kisunla treatment ends, while others maintain stability or continued modest improvement. The return of symptoms does not mean Kisunla failed—it means the disease resumed its natural course without the medication actively slowing it. This distinction is important because it shapes expectations: Kisunla slows decline, not halts or reverses it permanently.
When decline resumes, doctors face a decision tree: whether to restart Kisunla if it’s available through retreatment protocols, move to a different amyloid-targeting drug, or focus on supportive therapies and caregiving adjustments. A patient who experienced apparent benefit from Kisunla but declined after stopping might be a candidate for retreatment, though this depends on how long they remained stable and what their current amyloid and tau status is on imaging. Some families interpret resuming decline as a reason to try another approach; others recognize that some slowing of progression is better than no intervention at all.
Managing Amyloid-Related Imaging Abnormalities (ARIA)
During and after Kisunla treatment, the brain can develop side effects visible on MRI called amyloid-related imaging abnormalities (ARIA). These include amyloid-related imaging abnormality microhemorrhages (ARIA-E, seen as small bleeds or swelling) and microinfarcts. The presence of ARIA on post-treatment scans doesn’t always cause symptoms—many people have ARIA on imaging without noticing cognitive or physical changes—but it requires ongoing monitoring and may limit whether future amyloid-targeting treatments can be used.
A key tradeoff with Kisunla treatment is that it can reduce amyloid plaques while increasing the risk of ARIA, particularly in people with certain genetic risk factors like the APOE4 gene variant. After treatment ends, existing ARIA typically doesn’t worsen on its own, but it’s documented in the medical record and becomes a permanent consideration in future treatment decisions. Someone who develops symptomatic ARIA during treatment—such as headaches, confusion, or visual changes—may require ongoing neurological evaluation even after Kisunla is stopped.
Adjusting Medications and Managing Side Effects
Many people taking Kisunla use blood pressure medications to help manage ARIA risk, and these medications often continue after Kisunla treatment ends because blood pressure control remains important for brain health independent of the disease-modifying therapy. However, some medications may be adjusted or discontinued once the specific risks of Kisunla infusions are no longer present.
Cognitive and behavioral symptoms sometimes improve after Kisunla treatment, sometimes stabilize, and sometimes continue progressing despite treatment. If depression, anxiety, or behavioral changes emerge or worsen after treatment ends, these typically respond to psychiatric medications and counseling rather than to further Kisunla. A limitation of post-treatment care is that no single medication addresses all the non-memory aspects of Alzheimer’s disease, so multidisciplinary management becomes increasingly important.
Caregiving and Lifestyle Adjustments After Treatment
Families often hope that completing Kisunla means they can relax caregiving vigilance or reduce support structures, but the disease continues regardless of treatment status. The practical reality is that caregiving intensity depends on the person’s functional level after treatment, not on having completed a medication regimen. Someone who maintained independence during Kisunla treatment may remain independent after it ends; someone who required assistance before treatment typically still requires assistance afterward.
Lifestyle factors—cognitive engagement, physical activity, social connection, sleep, and diet—don’t become less important after a disease-modifying medication ends. If anything, these factors become more critical as the medication’s effect wanes. A patient who maintained exercise, social activities, and cognitive stimulation during Kisunla treatment may see better post-treatment outcomes than someone who reduced these activities while hoping medication alone would prevent decline.
Planning for Subsequent Treatments or Care Transitions
After Kisunla treatment completes, the neurologist and care team should discuss what happens if cognitive decline resumes: whether retreatment is an option, what alternative medications might be considered, and at what functional level the focus shifts from disease-modifying therapy to comfort and quality of life. This conversation is difficult but necessary because it prevents crisis decision-making when urgent choices arise. Some patients move from Kisunla to other disease-modifying therapies like lecanemab if they’re eligible and choose to continue amyloid-targeting treatment.
Others choose supportive care focused on managing symptoms, maintaining function, and improving quality of life without further disease-modifying drugs. The choice depends on treatment response, development of ARIA, personal values, and practical factors like travel requirements for infusions and side effect tolerability. Post-treatment planning should include how the care team will communicate with primary care doctors, specialists, and the person and family themselves about what cognitive changes represent normal disease progression versus warning signs that require urgent evaluation.
Frequently Asked Questions
Does Kisunla cure Alzheimer’s disease?
No. Kisunla slows cognitive decline in early Alzheimer’s disease but does not cure or reverse the disease. After treatment ends, the underlying disease continues to progress, though some benefit may persist.
How often do I need brain imaging after Kisunla treatment ends?
Imaging schedules vary by individual and clinical guidelines, but follow-up MRI or PET scans are typically performed at regular intervals—ranging from several months to annually—to monitor amyloid levels and watch for amyloid-related imaging abnormalities.
Can I restart Kisunla if cognitive decline returns?
Retreatment may be an option depending on your current disease status, whether you developed ARIA during initial treatment, and whether Kisunla remains medically appropriate for you. This decision requires discussion with your neurologist.
What is ARIA and why does it matter after treatment?
ARIA refers to microbleeds or microinfarcts that can develop as the brain clears amyloid plaques. Most people with ARIA on imaging have no symptoms, but it’s documented for future treatment planning and requires ongoing monitoring.
Will my symptoms improve after completing Kisunla?
Kisunla slows decline rather than improving symptoms. Some people experience modest cognitive improvements or stabilization during treatment, but symptoms typically do not dramatically improve, and decline may resume after treatment ends without ongoing monitoring and possible additional interventions.
